

## ASX Announcement

### Monash IVF Group Limited (ASX:MVF)

20 May 2025

## Monash IVF Group FY2025 Profit Guidance Update

Monash IVF Group Limited (ASX: MVF, the “Company” or “Monash IVF”) is today providing an update on anticipated Underlying NPAT<sup>1</sup> for the year ending 30 June 2025.

Monash IVF now expects FY25 Underlying Group NPAT<sup>1</sup> to be approximately \$27.5m, compared to previously provided guidance at the time of the release of the Company’s 2025 financial year first half results (1H25 results) on 27 February 2025 of between \$30.0m and \$31.0m.

The revised guidance reflects the Company’s assessment of softer market and operating conditions in March 2025 that worsened in April 2025 across all of the Company’s geographic markets. Operating conditions have improved in May 2025 with month-to-date at stronger levels than March and April but not sufficiently to offset the impact from these months.

The Company continues to monitor key indicators and any implications that may arise from the Brisbane incident announced on 11 April 2025, including Queensland and Australian new IVF patient registrations, returning IVF patients for stimulated cycles and frozen embryo transfers, and transfer of medical records and human material to alternative IVF providers. These indicators are currently consistent with the performance levels observed in the months leading up to the announcement of the Brisbane incident.

Monash IVF will release its FY25 results on 22 August 2025 and otherwise will keep the ASX informed of further information as required by its disclosure obligations.

Authorised by the Board of Directors.

**ENDS**

---

<sup>1</sup> Underlying NPAT is a non-IFRS measure and is before the non-regular items referred to in its 1H25 Results announcement on 27 February 2025 comprising commissioning of new premises in Brisbane (QLD) and Singapore, NiPGT class action related costs and settlement, impairment of an investment in an Associate and non-cash AASB16 Lease Accounting impact. In addition, FY25 non-regular items will now include costs for the Fiona McLeod AO SC Independent Report on the Brisbane incident and other related legal and advisory costs.

For further information please contact:

**Michael Knaap**

Chief Executive Officer & Managing Director

Monash IVF Group

T: +61 3 9420 8235

**Malik Jainudeen**

Chief Financial Officer & Company Secretary

Monash IVF Group

T: +61 3 9420 8235